SEC EDGAR published this disclosure on 2026-09-10. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0002150331-26-000002
acquired disposedA
codeA
direct or indirectD
form4
is derivativetrue
issuer nameLyell Immunopharma, Inc.
labelGrant or award
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0002150331-26-000002",
"acquired_disposed": "A",
"code": "A",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": true,
"issuer_name": "Lyell Immunopharma, Inc.",
"label": "Grant or award",
"person_name": "Aguirre Jarrad Mattieu",
"price": 0,
"role": "Chief Medical Officer",
"security": "Option (right to buy)",
"shares": 47500,
"shares_owned_after": 47500,
"source_path": "edgar/data/2150331/0002150331-26-000002.txt",
"ticker": "LYEL",
"transaction_date": "2026-09-10",
"value": null
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.